{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:18:13Z","timestamp":1790947093414,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Eyebrow and eyelash (EB\/EL) involvement is an important consideration in the assessment of alopecia areata (AA) severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To report on the integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259), characterizing EB\/EL involvement at baseline in patients with AA and response to baricitinib treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) were randomized double-blind placebo-controlled trials conducted at 169 centres in 10 countries. Patients were randomized to placebo, baricitinib 2\u2005mg or baricitinib 4\u2005mg. Pooled data from patients continually treated with baricitinib through week 52 were included. Outcomes were assessed using a clinician-reported outcome (ClinRO) measure for EB\/EL and Severity of Alopecia Tool (SALT) score for the scalp.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, patients with more severe EB\/EL involvement had more severe scalp hair loss, with mean SALT scores ranging from 70.6 to 96.0 for patients with no gaps to complete absence of hair, respectively, at EB\/EL sites. EB\/EL response rates [ClinRO (0,1) with \u2265 1-point improvement] at week 36 were significantly higher in patients treated with baricitinib 2\u2005mg [EB: 28.2%, odds ratio (OR) 3.27; EL: 25.1%, OR 2.95] and baricitinib 4\u2005mg (EB: 44.3%, OR 6.84; EL: 46.4%, OR 8.21) compared with placebo (EB: 12.6%; EL: 12.4%). There was high concordance between EB response and EL response, with approximately 80% of patients who achieved hair regrowth at one site achieving regrowth at the other, with baricitinib 4\u2005mg. Among scalp responders (SALT score \u2264 20 at week 52), 78.5% (n = 95\/121) and 82.6% (n = 100\/121) achieved an EB and EL response, respectively, and 71.1% (n = 86\/121) of patients achieved EB and EL responses with baricitinib 4\u2005mg. Among scalp nonresponders (SALT score &amp;gt; 20 at week 52), 46.7% (n = 91\/195) and 48.7% (n = 95\/195) achieved EB and EL responses, respectively, and 35.4% (n = 69\/195) achieved responses in both EB and EL. Similar trends but lower response rates were observed with baricitinib 2\u2005mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Baseline severity of EB\/EL involvement paralleled that of the scalp. Baricitinib was efficacious in achieving a holistic response across all three hair-bearing sites in the majority of week-52 scalp responders. These data detail the benefits of baricitinib across important hair-bearing sites involved in AA and highlight that individual patient treatment success should account for the totality of the clinical presentation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf088","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T07:48:04Z","timestamp":1743580084000},"page":"240-249","source":"Crossref","is-referenced-by-count":11,"title":["Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Craiglow","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[{"name":"Dermatology Physicians of Connecticut , Fairfield, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"New York University Langone Health , New York City, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ko","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyorin University Faculty of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Brogan","sequence":"additional","affiliation":[{"name":"Tigermed-BDM Inc. , Somerset, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Sontag","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2025071703165812100_ljaf088-B1","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025071703165812100_ljaf088-B2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2025071703165812100_ljaf088-B3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2025071703165812100_ljaf088-B5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","article-title":"\u2018\u201cYou lose your hair, what's the big deal?\u201d I was so embarrassed, I was so self-conscious, I was so depressed:\u2019 a qualitative interview study to understand the psychosocial burden of alopecia areata","volume":"4","author":"Aldhouse","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2025071703165812100_ljaf088-B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","article-title":"Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata","volume":"21","author":"Wyrwich","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2025071703165812100_ljaf088-B9","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jisp.2020.05.006","article-title":"The role of patients in alopecia areata endpoint development: understanding physical signs and symptoms","volume":"20","author":"Wyrwich","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025071703165812100_ljaf088-B10","doi-asserted-by":"crossref","first-page":"20141294","DOI":"10.1098\/rsif.2014.1294","article-title":"Eyelashes divert airflow to protect the eye","volume":"12","author":"Amador","year":"2015","journal-title":"J R Soc Interface"},{"key":"2025071703165812100_ljaf088-B11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1068\/p5027","article-title":"The role of eyebrows in face recognition","volume":"32","author":"Sadr","year":"2003","journal-title":"Perception"},{"key":"2025071703165812100_ljaf088-B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2023.5869","article-title":"The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity","volume":"160","author":"Moussa","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025071703165812100_ljaf088-B15","doi-asserted-by":"crossref","first-page":"e13053","DOI":"10.1111\/dth.13053","article-title":"The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review","volume":"32","author":"de Oliveira","year":"2019","journal-title":"Dermatol Ther"},{"key":"2025071703165812100_ljaf088-B16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3\u2005years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025071703165812100_ljaf088-B17","doi-asserted-by":"crossref","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6\u2005years and up to 3.9\u2005years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025071703165812100_ljaf088-B18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025071703165812100_ljaf088-B19","author":"Vleugels"},{"key":"2025071703165812100_ljaf088-B20","author":"Kwon"},{"key":"2025071703165812100_ljaf088-B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20334","article-title":"Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow\/eyelash regrowth in the first year","author":"Mostaghimi","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025071703165812100_ljaf088-B22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025071703165812100_ljaf088-B23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025071703165812100_ljaf088-B24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines \u2013 Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B25","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jisp.2020.04.006","article-title":"Eyebrows are important in the treatment of alopecia areata","volume":"20","author":"Liu","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025071703165812100_ljaf088-B26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaad.2018.11.037","article-title":"Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B27","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.jaad.2021.09.056","article-title":"It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis","volume":"87","author":"Peterson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025071703165812100_ljaf088-B28","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s13555-023-01063-2","article-title":"Clinical benefits of baricitinib therapy according to scalp hair regrowth in patients with severe alopecia areata","volume":"13","author":"Senna","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025071703165812100_ljaf088-B29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamadermatol.2020.5732","article-title":"Evaluation of stigma toward individuals with alopecia","volume":"157","author":"Creadore","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025071703165812100_ljaf088-B30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf088\/62857084\/ljaf088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/2\/240\/62857084\/ljaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/2\/240\/62857084\/ljaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T07:17:04Z","timestamp":1752736624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/2\/240\/8105643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,3]]},"published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf088","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,3]]}}}